NVCT
Nuvectis Pharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Nuvectis Pharma, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Feb 11 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 11 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Nuvectis Pharma, Inc.'s 3 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Nuvectis Pharma, Inc.'s 3 closest co-movers, none share that code.
Closest co-movers · 501d
DFTXDefinium Therapeutics×0.28r 0.33ABSIAbsci×0.32r 0.29UPSTUpstart Holdings×0.23r 0.26Nuvectis Pharma, Inc.
18.70
−0.64 · −3.32%
post 18.70 0.00%
| Manager | Value | % base | |
|---|---|---|---|
| Tang | $28.5M | 14.56% | new |
| BlackRockindex-like | $18.4M | 9.41% | +30.98% |
| Perceptive | $18.4M | 9.39% | new |
| Soleus | $18.4M | 9.39% | new |
| Vanguardindex-like | $16.0M | 8.20% | +32.22% |
| Manager | Value | % base | |
|---|---|---|---|
| Tang | $28.5M | 14.56% | new |
| BlackRockindex-like | $18.4M | 9.41% | +30.98% |
| Perceptive | $18.4M | 9.39% | new |
| Soleus | $18.4M | 9.39% | new |
| Vanguardindex-like | $16.0M | 8.20% | +32.22% |
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
—
—
Expected move
No implied move.